Prediction of Outcome After Endovascular Embolectomy in Anterior Circulation Stroke Using Biomarkers

[1]  A. Privat,et al.  GFAP null astrocytes are a favorable substrate for neuronal survival and neurite growth , 2000, Glia.

[2]  K. Blennow,et al.  Normal levels of clusterin in cerebrospinal fluid in Alzheimer's disease, and no change after acute ischemic stroke. , 2001, Journal of Alzheimer's disease : JAD.

[3]  M. Kirschner,et al.  A protein factor essential for microtubule assembly. , 1975, Proceedings of the National Academy of Sciences of the United States of America.

[4]  R. Fukuyama,et al.  The Cerebrospinal Fluid Level of Glial Fibrillary Acidic Protein Is Increased in Cerebrospinal Fluid from Alzheimer’s Disease Patients and Correlates with Severity of Dementia , 2001, European Neurology.

[5]  K. Blennow,et al.  Serum neurofilament light as a biomarker for mild traumatic brain injury in contact sports , 2017, Neurology.

[6]  F. Michetti,et al.  Immunochemical and immunocytochemical localization of S-100 antigen in normal human skin , 1981, Nature.

[7]  O. Sogut,et al.  Trauma Scores and Neuron-Specific Enolase, Cytokine and C-Reactive Protein Levels as Predictors of Mortality in Patients with Blunt Head Trauma , 2010, The Journal of international medical research.

[8]  Fares Alahdab,et al.  Global, regional, and national burden of stroke, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 , 2019, The Lancet Neurology.

[9]  P. Bottoni,et al.  Neuron-Specific Enolase as a Biomarker: Biochemical and Clinical Aspects. , 2015, Advances in experimental medicine and biology.

[10]  B. Moore.  A soluble protein characteristic of the nervous system. , 1965, Biochemical and biophysical research communications.

[11]  A. Demchuk,et al.  Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials , 2016, The Lancet.

[12]  H. Nawashiro,et al.  Mice lacking GFAP are hypersensitive to traumatic cerebrospinal injury , 1998, Neuroreport.

[13]  Henrik Zetterberg,et al.  Levels and Age Dependency of Neurofilament Light and Glial Fibrillary Acidic Protein in Healthy Individuals and Their Relation to the Brain Parenchymal Fraction , 2015, PloS one.

[14]  J. Sobesky,et al.  Prognostic value of somatosensory evoked potentials, neuron-specific enolase, and S100 for short-term outcome in ischemic stroke. , 2016, Journal of neurophysiology.

[15]  K. Blennow,et al.  Plasma and cerebrospinal fluid tau and neurofilament concentrations in rapidly progressive neurological syndromes: a neuropathology‐based cohort , 2017, European journal of neurology.

[16]  A. González-Quevedo,et al.  Short-term prognostic value of serum neuron specific enolase and S100B in acute stroke patients. , 2012, Clinical biochemistry.

[17]  R. Perrot,et al.  Neuronal intermediate filaments and neurodegenerative disorders , 2009, Brain Research Bulletin.

[18]  R. Hayes,et al.  Assessment of Serum UCH-L1 and GFAP in Acute Stroke Patients , 2016, Scientific Reports.

[19]  J. Cronly-Dillon,et al.  Preferential histochemical staining of protoplasmic and fibrous astrocytes in rat CNS with GFAP antibodies using different fixatives , 1990, Brain Research.

[20]  K. Blennow,et al.  Neurofilament changes in serum and cerebrospinal fluid after acute ischemic stroke , 2019, Neuroscience Letters.

[21]  G. Davies-Jones,et al.  Cerebrospinal fluid enolase in stroke. , 1984, Journal of neurology, neurosurgery, and psychiatry.

[22]  K. Muir,et al.  How many stroke patients might be eligible for mechanical thrombectomy? , 2016, European stroke journal.

[23]  C. Price,et al.  Estimating the number of UK stroke patients eligible for endovascular thrombectomy , 2017, European stroke journal.

[24]  D. DeMets,et al.  Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework , 2001, Clinical pharmacology and therapeutics.

[25]  M. Sitzer,et al.  Characterisation of the Diagnostic Window of Serum Glial Fibrillary Acidic Protein for the Differentiation of Intracerebral Haemorrhage and Ischaemic Stroke , 2008, Cerebrovascular Diseases.

[26]  K. Blennow,et al.  Journal of Central Nervous System Disease , 2022 .

[27]  J. Silver,et al.  Glial fibrillary acidic protein is necessary for mature astrocytes to react to beta-amyloid. , 1999, Glia.

[28]  M. Deckert,et al.  The Intermediate Filament GFAP Is Important for the Control of Experimental Murine Staphylococcus aureus‐Induced Brain Abscess and Toxoplasma Encephalitis , 2004, Journal of neuropathology and experimental neurology.

[29]  A. Demchuk,et al.  Use of the Alberta Stroke Program Early CT Score (ASPECTS) for assessing CT scans in patients with acute stroke. , 2001, AJNR. American journal of neuroradiology.

[30]  K. Blennow,et al.  Neurogranin and tau in cerebrospinal fluid and plasma of patients with acute ischemic stroke , 2017, BMC Neurology.

[31]  G. Jullien,et al.  Therapeutic application of the molecular adsorbent recirculating system in chronic severe hepatitis patients complicated with multiorgan failure , 2005, Critical Care.

[32]  L. Rosengren,et al.  Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis , 2010, Journal of Neurology.

[33]  K. Blennow,et al.  Cerebrospinal fluid markers for Alzheimer's disease evaluated after acute ischemic stroke. , 2000, Journal of Alzheimer's disease : JAD.

[34]  J. Noth,et al.  Gradual loss of myelin and formation of an astrocytic scar during Wallerian degeneration in the human spinal cord. , 2004, Brain : a journal of neurology.

[35]  M. Oblinger,et al.  Regional distribution and biochemical characteristics of high molecular weight tau in the nervous system , 1992, Journal of neuroscience research.

[36]  R. Thompson,et al.  Levels of immunoreactive aldolase C, creatine kinase-BB, neuronal and non-neuronal enolase, and 14-3-3 protein in circulating human blood cells. , 1984, Clinica chimica acta; international journal of clinical chemistry.

[37]  C. Heizmann,et al.  S100 proteins in mouse and man: from evolution to function and pathology (including an update of the nomenclature). , 2004, Biochemical and biophysical research communications.

[38]  L. Schneck.  Biochemical and Clinical Aspects , 1975 .

[39]  S. Mckinstry,et al.  Serum neurone‐specific enolase as an indicator of stroke volume , 1996, European journal of clinical investigation.

[40]  K. Blennow,et al.  Cerebrospinal fluid neurofilament light concentration in motor neuron disease and frontotemporal dementia predicts survival , 2017, Amyotrophic lateral sclerosis & frontotemporal degeneration.

[41]  M. Schluep,et al.  Glial and axonal body fluid biomarkers are related to infarct volume, severity, and outcome. , 2008, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[42]  N. Kowall,et al.  Immunohistochemical patterns of selective cellular vulnerability in human cerebral ischemia , 1993, Journal of the Neurological Sciences.

[43]  Volkmar Glauche,et al.  Diffusion tensor imaging detects early Wallerian degeneration of the pyramidal tract after ischemic stroke , 2004, NeuroImage.

[44]  M. Brenner.  Role of GFAP in CNS injuries , 2014, Neuroscience Letters.

[45]  B. Romner,et al.  Biochemical serum markers for brain damage: a short review with emphasis on clinical utility in mild head injury. , 2003, Restorative neurology and neuroscience.

[46]  L. Hagberg,et al.  Difference in pathogenesis between herpes simplex virus type 1 encephalitis and tick-borne encephalitis demonstrated by means of cerebrospinal fluid markers of glial and neuronal destruction , 2000, Journal of Neurology.

[47]  G. D. De Marchis,et al.  Serum neurofilament light chain in patients with acute cerebrovascular events , 2018, European journal of neurology.

[48]  J. Silver,et al.  Glial fibrillary acidic protein is necessary for mature astrocytes to react to β‐amyloid , 1999 .

[49]  Ji‐Hyung Park,et al.  Prediction of early clinical severity and extent of neuronal damage in anterior-circulation infarction using the initial serum neuron-specific enolase level. , 2003, Archives of neurology.

[50]  P. Carmeliet,et al.  Protective Role of Reactive Astrocytes in Brain Ischemia , 2008, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[51]  Lynn Babcock,et al.  Are UCH-L1 and GFAP promising biomarkers for children with mild traumatic brain injury? , 2016, Brain injury.

[52]  Thomas Brott,et al.  The impact of imbalances in baseline stroke severity on outcome in the National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study. , 2005, Annals of emergency medicine.

[53]  E. Mandelkow,et al.  Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress , 2002, The Journal of cell biology.

[54]  Leslie Wilson,et al.  Inability of tau to properly regulate neuronal microtubule dynamics: a loss-of-function mechanism by which tau might mediate neuronal cell death. , 2005, Biochimica et biophysica acta.

[55]  J. Kacza,et al.  Decline of microtubule-associated protein tau after experimental stroke in differently aged wild-type and 3xTg mice with Alzheimer-like alterations , 2016, Neuroscience.

[56]  F. Goodwin,et al.  Neuronal, non-neuronal and hybrid forms of enolase in brain: Structural, immunological and functional comparisons , 1978, Brain Research.

[57]  M. Seipelt,et al.  Serum Tau Protein Level as a Marker of Axonal Damage in Acute Ischemic Stroke , 2002, European Neurology.

[58]  M. Skalej,et al.  Neuron-specific enolase and tau protein as neurobiochemical markers of neuronal damage are related to early clinical course and long-term outcome in acute ischemic stroke , 2006, Clinical Neurology and Neurosurgery.

[59]  R. Liem,et al.  α-Internexin and Peripherin: Expression, Assembly, Functions, and Roles in Disease. , 2016, Methods in enzymology.

[60]  M. Brown,et al.  Criteria for a Clinically Informative Serum Biomarker in Acute Ischaemic Stroke: A Review of S100B , 2009, Cerebrovascular Diseases.

[61]  L. Rosengren,et al.  Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis , 1998, Journal of neurology, neurosurgery, and psychiatry.

[62]  P. Carmeliet,et al.  Under stress, the absence of intermediate filaments from Müller cells in the retina has structural and functional consequences , 2004, Journal of Cell Science.

[63]  I. Bechmann,et al.  Up-regulation of neurofilament light chains is associated with diminished immunoreactivities for MAP2 and tau after ischemic stroke in rodents and in a human case , 2016, Journal of Chemical Neuroanatomy.

[64]  M. Hellström,et al.  General Anesthesia Versus Conscious Sedation for Endovascular Treatment of Acute Ischemic Stroke: The AnStroke Trial (Anesthesia During Stroke) , 2017, Stroke.

[65]  T. Crawford,et al.  Subunit composition of neurofilaments specifies axonal diameter , 1996, The Journal of cell biology.

[66]  K. Haglid,et al.  Determination of S‐100 and Glial Fibrillary Acidic Protein Concentrations in Cerebrospinal Fluid After Brain Infarction , 1991, Stroke.

[67]  M. Brown,et al.  Hyperacute Detection of Neurofilament Heavy Chain in Serum Following Stroke: A Transient Sign , 2011, Neurochemical Research.

[68]  F. Beyersdorf,et al.  Neuron-specific enolase correlates to laboratory markers of haemolysis in patients on long-term circulatory support. , 2015, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[69]  E. Mandelkow,et al.  Tau in physiology and pathology , 2015, Nature Reviews Neuroscience.

[70]  K. Blennow,et al.  Serum neurofilament light protein predicts clinical outcome in traumatic brain injury , 2016, Scientific Reports.

[71]  J. Broderick,et al.  Association of Serial Biochemical Markers With Acute Ischemic Stroke: The National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study , 2006, Stroke.

[72]  Henrik Zetterberg,et al.  Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa , 2016, Clinical chemistry and laboratory medicine.

[73]  Henrik Zetterberg,et al.  Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression. , 2016, JAMA neurology.

[74]  M. L. Schmidt,et al.  Distribution of tau proteins in the normal human central and peripheral nervous system. , 1989, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[75]  E. Baudin,et al.  Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours. , 1998, British Journal of Cancer.

[76]  C. Wikkelsø,et al.  Patients with Amyotrophic Lateral Sclerosis and Other Neurodegenerative Diseases Have Increased Levels of Neurofilament Protein in CSF , 1996, Journal of neurochemistry.

[77]  V. Seifert,et al.  Serum S-100B protein as a molecular marker in severe traumatic brain injury. , 2003, Restorative neurology and neuroscience.